Craig Polson

Craig Polson's work experience includes roles at various pharmaceutical and biotechnology companies.

From 2018 to the present, they worked as a Research Scientist at Arvinas.

From 2017 to 2018, they held the position of Research Scientist II at Celldex Therapeutics.

Before that, from 2002 to 2017, they worked at Bristol-Myers Squibb, where they held several roles, including Sr. Research Scientist II and Senior Research Scientist I. In these roles, they were responsible for progressing pre-clinical programs in tau for Alzheimer's Disease and Progressive Supranuclear Palsy, synuclein for Multiple System Atrophy, and Parkinson's Disease towards clinical development. Craig coordinated a system to rank anti-synuclein antibodies for clinical development and used liquid chromatography to isolate and track the activity of potential disease-causing species. Craig also played a crucial role in biomarker discovery and development for the company's programs, leading to the identification of a toxicity biomarker for the γ-secretase inhibitor program for Alzheimer's Disease. Craig developed various protocols and screening platforms to study the effects of Aβ modulators and γ-secretase inhibitors.

Craig Polson attended Boston University from 1987 to 1991, where they obtained a Bachelor of Arts (BA) degree in Psychology and Biology.